Clinical Trial Registry Data: A Roadmap for Better Use, Not Yet a Map to Better Evidence

IJsbrand den Rooijen, Giacomo Capone, Jacobus van Wyk, et al.

Summary: A January 2024 workshop held under the European Union's Accelerating Clinical Trials (ACT EU) initiative examined nearly 55,000 clinical trials recorded in European registries and asked how that data could be put to better use. The workshop identified three main opportunities: using historical registry records to design better future trials, making trials more focused on what patients need, and helping regulators and policymakers evaluate evidence more reliably. The authors also identified four things that need to happen before any of that is possible — standardizing how data are recorded, improving data quality, making different registries able to communicate with each other, and increasing transparency. One early, concrete output is a patient-facing tool called the ACT EU trial map, developed by the European Medicines Agency to help patients find relevant trials.

Why it matters: Clinical trial registries hold a large amount of information that is rarely used once a trial ends. If that data were made consistent and connected across registries, researchers could avoid designing trials that duplicate work already done, identify where evidence is missing, and help regulators make decisions more quickly. For people with rare conditions — where the number of patients in any single study is small — the ability to combine and compare records across many trials could be especially valuable.

What to keep in mind: This article reports the conclusions of a workshop discussion, not the results of a research study, so its ideas have not been tested against real-world outcomes. The four improvements the authors call for — standardization, quality, interoperability, and transparency — are widely recognized as the right goals, but they are also long-standing obstacles that have been difficult to achieve across different countries, institutions, and regulatory bodies. The patient-facing trial map is a useful first step, but a searchable tool for patients is a modest beginning relative to the full vision described. Whether the ACT EU initiative can turn these workshop conclusions into lasting infrastructure change remains an open question.

Relevance: Patient Registries | Real-World Data | Data Standards | Interoperability | Regulatory Science

Source: https://pubmed.ncbi.nlm.nih.gov/42881013/

---